University of Chicago
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).
University of Chicago: 796 sponsored US clinical trials, 158 recruiting.
University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.
Top-decile sponsor footprint
University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
796 total, page 2 of 16
Pathobiomes in Gut of Critically Ill Patients
NCT06822465
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
NCT06663072
Hemodynamic ABI Monitor
NCT06725108
Objective Assessment of Outcomes Following Immediate Lymphatic Reconstruction / LYMPHA
NCT06650592
Genicular Nerve Block After Open Reduction Internal Fixation of Tibial Plateau
NCT06639503
Reducing Disparities in Urinary Control Symptoms for Minority Women
NCT06798311
Immune Status After Being on Call for 24 Hrs
NCT06636318
Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition
NCT06094478
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
NCT06291987
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
NCT06207123
A Novel Intervention for Weight Loss in Young Adults
NCT06230744
Dex +/- Caffeine Sedation in a Post-MRI Recovery in a Pediatric Population
NCT06538584
Intensive Patient Referral and Education Program Prior to Renal Replacement Therapy
NCT06397456
Communication Bridge 3 Study
NCT06191198
J-RISE: Relevant Implementation Strategies to Eliminate the Social and Structural Barriers to HIV Services Among Justice-involved Black Men Who Have Sex With Men and Other Key Populations
NCT06477588
Comprehensive Geriatric Assessment (Tests) for Bladder Cancer Participants Undergoing Radical Cystectomy
NCT06427824
Brain Function Monitoring During Surgery
NCT06619730
Informing Pain Treatment Using Pharmacogenomic Analysis
NCT06511401
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
NCT05108870
Patient Outcome Reporting for Timely Assessments of Life With Post-Traumatic Stress Disorder
NCT06479447
Let's E.A.T.! (Eating With Assistive Technology): An Intervention to Support Children With Feeding Tubes and Tracheostomies
NCT06525818
Dime La VerDAD: Verify, Debunk, and Disseminate
NCT06417762
Kidney Stone Inflammation
NCT06436235
Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery
NCT06349590
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
NCT06705803
Posterior Rectus Sheath Hiatal Augmentation in Paraesophageal Hernia Repair
NCT06551077
Get Fit for Function
NCT06359652
Metabolic Endpoints for Obstructive Sleep Apnea Following Twelfth Cranial Nerve Stimulation
NCT06317701
Changes in Glucose Tolerance in Patients With Cirrhosis Peri-Liver Transplant
NCT06950788
Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)
NCT06305286
Feasibility of a Dog Training Therapy Program in UC Outpatient Youth Receiving Psychiatric Services
NCT05788783
Prevention of Postoperative Atrial Fibrillation (POAF) Using Intra-Pericardial Amiodarone
NCT06063538
Durometer for Measuring Uterine Tone
NCT06284421
Oxygenation in Vascular Lesions of the Colon
NCT06230731
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
NCT06171152
Quantitative Assessment of Autologous Fat Transfer
NCT06343831
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
NCT06171269
Combining Biomarkers and Electronic Risk Scores to Predict AKI in Hospitalized Patients
NCT05988658
Video Training Supplementation for Patients Discharged on Home Parental Nutrition
NCT06169774
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
NCT06005324
Biobank Cardiac Surgery
NCT06747806
Percutaneous Nerve Evaluation Trial Time
NCT06226220
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
NCT05886764
Creation of a Prospective Data Collecting Registry for Genicular Artery Embolization for Arthritis
NCT06781463
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
NCT02747303
Chicago Asthma School-Directed Child-Centered Assessment and Dissemination of Evidence
NCT06320210
PrEP Optimization Among Women to Enhance Retention and Uptake
NCT05626452
Tissue Destruction and Healing in Celiac Disease
NCT05680012
Cardiac Power Output in Cardiogenic Shock Patients
NCT05700617
A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection
NCT06008860
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 137 |
| Phase 2 | 156 |
| Phase 3 | 14 |
| Phase 4 | 53 |
Therapeutic Areas
What is open in the University of Chicago pipeline
158 recruiting of 796 indexed (20% open); 451 completed (57%).
Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (11 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Chicago: open-pipeline peers nationwide
Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 796 trials (± recruiting share)
- Dana-Farber Cancer Institute · 781 trials · 14% recruiting
- University of California, San Diego · 775 trials · 18% recruiting
- University of Utah · 818 trials · 17% recruiting
- University of Texas Southwestern Medical Center · 837 trials · 19% recruiting
Sponsors near 20% open enrollment (± trial volume)
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
- AltruBio · 20% recruiting · 5 trials
- Alvernia University · 20% recruiting · 5 trials
Related
What to do with this University of Chicago page
796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.
- 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Chicago pipeline card: 796 registered trials from official public datasets.Report a data error.